Browse Category

Stock Market News 13 January 2026

ServiceNow stock drops as Oppenheimer trims target — what to watch before earnings

ServiceNow stock drops as Oppenheimer trims target — what to watch before earnings

New York, January 13, 2026, 15:01 ET — Regular session ServiceNow (NOW) slipped 3.3% to $137.95 in afternoon trading Tuesday, following Oppenheimer’s cut to its price target—from $230 down to $200—though the firm kept an “Outperform” rating. The stock underperformed the iShares Expanded Tech-Software Sector ETF, which dropped roughly 2%. This matters as the company prepares to release results amid investor debate over whether enterprise software spending is holding steady or fluctuating. ServiceNow offers cloud software that automates business workflows — exactly the kind of expense that comes under the microscope when budgets tighten. Wall Street turned choppy for growth
Ofwat warns on South East Water outage as Severn Trent, United Utilities shares fall

Ofwat warns on South East Water outage as Severn Trent, United Utilities shares fall

London, Jan 13, 2026, 19:47 GMT Shares in London-listed water utilities dropped Tuesday as regulators and politicians ramped up scrutiny on South East Water following a fresh outage that left around 25,000 homes in Kent and Sussex without steady water supply. Severn Trent slid 2.6%, United Utilities lost 1.9%, and Pennon closed down 1.7%. (https://www.investing.com/equities/severn-trent https://www.investing.com/equities/united-utilities https://www.investing.com/equities/pennon) Ofwat, the regulator for water services, said it was “concerned” and plans to review the evidence before deciding if South East Water has met its legal duties on customer care. The latest outages, attributed to Storm Goretti and burst pipes, left some households
Adobe stock slides after Oppenheimer downgrade as AI threat looms for ADBE

Adobe stock slides after Oppenheimer downgrade as AI threat looms for ADBE

New York, Jan 13, 2026, 14:40 EST Adobe shares dropped Tuesday following a downgrade from Oppenheimer, marking another cautious note among recent calls that have pressured the stock this month. By afternoon, shares had fallen 5.7% to $309.02. The downgrade hits at a crucial moment for Adobe, perched on the edge of the AI trade. Investors crave quicker returns from generative-AI features, but analysts are zeroing in on whether these new tools could open the door for competitors to chip away at Adobe’s core business. Oppenheimer called the 2026 outlook for application software “challenging,” noting the sector has underperformed the
AbbVie stock nudges lower after Trump drug-price pact; traders watch JPM talk, Feb. 4 results

AbbVie stock nudges lower after Trump drug-price pact; traders watch JPM talk, Feb. 4 results

New York, January 13, 2026, 14:45 ET — Regular session AbbVie shares slipped 0.1% to $219.83 Tuesday afternoon after the drugmaker announced a three-year deal with the Trump administration. The pact aims to lower certain drug prices in return for exemptions from tariffs and future pricing rules. The deal arrives amid investor attempts to figure out how “lower prices” might impact big pharma in 2026 — and if Washington’s efforts will become a serious drag on margins or just a tolerable hit. It also brings trade policy into the pricing debate, a spot few shareholders anticipated focusing on this early
Alnylam stock dips as Amvuttra sales miss some forecasts; 2026 outlook in focus

Alnylam stock dips as Amvuttra sales miss some forecasts; 2026 outlook in focus

New York, January 13, 2026, 14:47 ET — During regular trading hours Shares of Alnylam Pharmaceuticals slipped 0.1% to $370.39 in Tuesday afternoon trading, as investors weighed the company’s updated sales forecast alongside its new five-year strategy. Based in Cambridge, Massachusetts, the company revealed preliminary 2025 sales and 2026 guidance in a Form 8-K tied to its “Alnylam 2030” plan. It warned that these figures are unaudited and may be revised before the full results come out in February. (StreetInsider.com) The news came through as executives and investors gathered at the annual J.P. Morgan Healthcare Conference, a key week when
Boeing stock jumps as deliveries hit 7-year high and orders beat Airbus

Boeing stock jumps as deliveries hit 7-year high and orders beat Airbus

NEW YORK, Jan 13, 2026, 14:39 EST Boeing (BA.N) shares jumped 2.6% to $246.04 in Tuesday afternoon trading following the announcement of its highest annual jet deliveries since 2018. The planemaker reported 600 aircraft delivered in 2025, a 72% increase, and net orders—bookings after cancellations—hit 1,075, surpassing Airbus’ 889. Airbus, however, still led in deliveries with 793 jets. Boeing’s finance chief said the company expects to generate positive cash flow in 2026, supported by increased commercial deliveries. (Reuters) Boeing’s cash flow hinges largely on jet deliveries, making the delivery count crucial. The company handed over 600 aircraft in 2025, a
Bharat Coking Coal IPO pulls in ₹1.1 lakh crore bids as grey-market signals lift debut hopes

Bharat Coking Coal IPO pulls in ₹1.1 lakh crore bids as grey-market signals lift debut hopes

Mumbai, Jan 14, 2026, 01:09 IST Bharat Coking Coal’s initial public offering closed in India on Tuesday with demand running about 147 times the shares on offer, exchange data showed. The grey market premium (GMP) — an unofficial price paid in off-market deals before listing — was around ₹11, implying a debut near ₹34 versus the top issue price of ₹23. (The Economic Times) The scramble comes despite choppy trading in domestic stocks, and it is a sharp test of risk appetite early in 2026. Bids topped ₹1.1 lakh crore (₹1.1 trillion) for the ₹1,071-crore issue, with applications crossing 90
Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13

Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13

NEW YORK, Jan 13, 2026, 14:32 (EST) — Regular session Shares of Ligand Pharmaceuticals Incorporated dropped 10.6% to $184.80 in Tuesday afternoon trading. The decline followed an announcement from royalty partner Travere Therapeutics that U.S. regulators extended the review period for its Filspari application, pushing the decision date to April 13. Travere said the FDA classified its latest submission as a “major amendment” but didn’t request additional safety or manufacturing data. LGND shares opened at $196.96 and fluctuated between $175.89 and $206.78. (Business Wire) The timing cuts deep, given this was a straightforward, immediate trigger for Ligand’s royalty setup. Traders
Coca-Cola stock edges up after KO sets Feb. 10 earnings date; CAGNY appearance next

Coca-Cola stock edges up after KO sets Feb. 10 earnings date; CAGNY appearance next

New York, January 13, 2026, 14:29 EST — Trading in regular session. Coca-Cola Co shares edged up about 0.5% to $70.83 on Tuesday after the company announced it will report fourth-quarter and full-year 2025 results on Feb. 10, ahead of the NYSE open, with an investor call scheduled for 8:30 a.m. ET. CEO-elect Henrique Braun and CFO John Murphy are also set to speak at the Consumer Analyst Group of New York conference in Orlando on Feb. 17. (The Coca-Cola Company) The timing is crucial, marking the next two key occasions when management must engage directly with investors rather than
American Airlines stock drops 3.5% as Delta outlook and credit-card rate-cap worries hit airline shares

American Airlines stock drops 3.5% as Delta outlook and credit-card rate-cap worries hit airline shares

New York, Jan 13, 2026, 14:28 EST — Regular session Shares of American Airlines Group dropped 3.5% to $15.44 in Tuesday’s afternoon session, lagging a softer airline sector following Delta’s latest forecast and new concerns over credit-card economics. Delta slid roughly 3%, United dropped about 1.4%, and Southwest lost around 1%. This shift is significant because airline investors have been relying more on “non-ticket” revenue—mainly loyalty programs linked to co-branded credit cards that offer points and miles. President Donald Trump’s plan to impose a one-year cap of 10% on credit-card interest rates, starting Jan. 20, has cast a spotlight on
Travere Therapeutics stock slides as FDA pushes Filspari FSGS decision into April

Travere Therapeutics stock slides as FDA pushes Filspari FSGS decision into April

New York, January 13, 2026, 14:17 (EST) — Regular session Shares of Travere Therapeutics (TVTX.O) dropped 19% to $27.56 in early afternoon trading Tuesday after the U.S. Food and Drug Administration extended its review of the kidney drug Filspari for broader use. The stock had fallen as much as 34% earlier, hitting a low of $22.35. (Reuters) The delay comes during a week investors saw as crucial for the small-cap drugmaker’s regulatory path. Winning an expanded label for focal segmental glomerulosclerosis (FSGS) would unlock a fresh market, beyond the drug’s existing approval for IgA nephropathy. Traders had pegged this decision
Pony AI stock slides nearly 10% in New York trade as rate bets reset after CPI

Pony AI stock slides nearly 10% in New York trade as rate bets reset after CPI

New York, Jan 13, 2026, 14:34 EST — Regular session Pony AI Inc shares dropped sharply on Tuesday, falling roughly 9.8% to $15.66 in afternoon trading. This slide pulled the autonomous-driving company’s stock well under Monday’s close of $17.37. The decline was significant since it targeted a high-growth stock sensitive to shifts in risk appetite and interest-rate forecasts. Tuesday’s data revealed U.S. consumer prices climbed 0.3% in December, marking a 2.7% increase from a year ago; core inflation, excluding food and energy, held steady at 2.6% year-over-year. (Bureau of Labor Statistics) Traders pushed up expectations for an earlier Federal Reserve

Stock Market Today

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop